Therapeutic potential of Lactococcus lactis D4 from fermented buffalo milk (Dadiah) against Staphylococcus aureus-induced diarrhea in mice Authors: Ade Sukma, Azura Adawiya, Elsa Badriyya, Najmiatul Fitria Published: 2026 ABSTRACT AbstractObjectives: This study aimed to evaluate the therapeutic potential of Lactococcus lactis D4 against diarrhea induced by Staphylococcus aureus in a mouse model.Materials and Methods: A randomized design was adopted using 25 male mice randomly assigned to five groups, which are negative control, positive control (diarrhea + cotrimoxazole), probiotic dose 1 (5 × 108 CFU/mice in 0.5 ml), probiotic dose 2 (administered twice, each administration containing 5 × 108 CFU/mice in 0.5 ml), and disease control (diarrhea without therapy). Diarrhea was induced with S. aureus (5 × 108 CFU/mouse in 0.5 ml), and thereafter, the probiotic was given orally for 7 days. The main parameters examined were body weight, fecal weight, and consistency.Results: Administration of L. lactis D4 improved diarrheal consequences (p < 0.05). The highest efficacy was observed at probiotic dose 2, containing 5 × 108 CFU/mouse in 0.5 ml twice a day. This improvement made a little body weight loss (31.04 gm) and improved fecal consistency.Conclusions: Lactococcus lactis D4 showed potential as an ecological probiotic for diarrheal therapy caused by S. aureus. These results supported the sustainable development goals (SDGs) of buffalo-derived functional foods to improve gut health (SDG 3) and informed sustainable strategies for global food security (SDGs 2, 9, and 12).Keywords: buffalo milk, diarrhea, Lactococcus lactis D4, mice, probiotics, SDG 3 1. Introduction Diarrhea remains a global health problem with high morbidity and mortality, especially among children in developing countries. The World Health Organization (WHO) reported approximately 1.7 billion cases of diarrhea every year. There are more than 400,000 deaths among children under five years old due to diarrhea [1]. Infective bacteria caused by Staphylococcus aureus are the major cause of diarrhea. Staphylococcus aureus is a Gram-positive bacterium that can lead to intestinal inflammation (healing and emptying the bowel) and disruption of the gut [2, 3, 4]. This bacteria can also invade the intestine and contribute to microbial dysbiosis [5]. The general remedy for diarrhea is antibiotics like cotrimoxazole and those tablets that have been commonly given by drug treatment. However, ongoing methicillin-resistant S. aureus (MRSA) strains in gastroenteritis have compromised conventional antibiotics such as cotrimoxazole [6]. This highlights the need for more sustainable alternative therapies. Probiotics have become a promising new option for diarrhea treatment. Probiotics are live microorganisms that can have positive effects on the gut microbiota, producing antimicrobial compounds and fortifying the intestinal barrier [7, 8]. Dadiah, a traditional buffalo milk fermentation product from West Sumatra, is known to contain various lactic acid bacteria, such as Lactococcus lactis [9, 10, 11, 12]. The L. lactis D4 (LD4) strain isolated from Dadiah produces lactisin as the most stable bacteriocin for the digestive response. This is widely approved as an antimicrobial target for S. aureus [9, 13]. But the effects of this probiotic on diarrhea caused by S. aureus infection are very limited [10, 14]. In this study, we attempted to investigate how well the oral suspension of L. lactis D4 taken from Dadiah induces diarrhea in mice with S. aureus based on body weight, fecal consistency, and fecal weight to support Sustainable Development Goals (SDGs). 2. Materials and Methods 2.1. Ethical approval This research complies with the ethical considerations of the Faculty of Pharmacy, Universitas Andalas, No. 77/UN16.10.D.KEPK-FF/2025. 2.2. Study design This study employed a completely randomized design (CRD) with an experimental approach [3, 15], following Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines from the Equator Network [3, 15]. 2.3. Experimental animal A total of 25 male mice (weighing 25–35 gm) were randomly assigned into five groups: Negative control: Healthy mice without diarrhea induction or therapy; positive control: Diarrhea + cotrimoxazole; treatment 1: Diarrhea + L. lactis D4 at a dose of 5 × 108 CFU/mouse in 0.5 ml; treatment 2: Diarrhea + L. lactis D4 at a dose administered twice, each administration containing 5 × 108 CFU/mouse in 0.5 ml; disease control: mice with diarrhea induction but without therapy. 2.4. Housing and husbandry Experimental mice were housed in standard plastic cages for acclimatization. Appropriate bedding and environmental conditions were controlled (22–25°C, 50–60%RH). Experimental mice were in a 12-h light/dark cycle. Animals had access to standard laboratory food and drinking water ad libitum throughout the study period, except during specific treatment procedures. The mice have wire-mesh bedding to sink their waste after treatment and to collect it. The feces were placed on white bedding to ensure clinical consistency, as shown in Figure 1. Animal housing. 2.5. Randomization and allocation Randomization was performed by the animal house staff of the Faculty of Pharmacy to minimize research bias. Following the acclimatization period, the mice were randomly allocated to five experimental groups (n = 5 per group) using simple randomization. The groups consisted of a negative control group comprising healthy mice without diarrhea induction or treatment; a disease control group in which mice were subjected to diarrhea induction without receiving any therapy; a positive control group of mice with diarrhea induction treated with cotrimoxazole; a treatment 1 group in which mice with diarrhea induction received L. lactis D4 at a dose of 5 × 108 CFU/mouse in 0.50 ml administered once daily; and a treatment 2 group in which mice with diarrhea induction were treated with L. lactis D4 administered twice daily, with each administration containing 5 × 108 CFU/mouse in 0.50 ml. 2.6. Induction of diarrhea Diarrhea was induced by administering a 0.5 ml oral suspension of S. aureus (109 CFU/ml) for 3 days until diarrhea symptoms appeared. The consistency of feces was assessed using a three-point scoring system for diarrhea to determine whether the feces were hard or normal, with pellets present. The scale was defined as follows: 1 = hard, normal stool; 2 = soft, full stool. The probiotic dose group received L. lactis D4 (109 CFU/ml), administered orally twice daily for 7 days following diarrhea induction, characterized by weight loss, increased fecal weight, and increasingly liquid fecal consistency. Cotrimoxazole was administered as a positive control at 0.40 ml orally for 7 days after diarrhea induction. 2.7. Preparation and treatment administration The L. lactis strain D4 isolate used in this study was obtained from the Animal Product Technology Laboratory, Faculty of Animal Husbandry, Andalas University. This isolate was obtained from fermented buffalo milk (Dadiah) in West Sumatra and underwent molecular identification and viability testing to confirm its suitability as a Customized Microbial Supplementation (CMS). The S. aureus isolate was obtained from the Animal Product Technology Laboratory at Andalas University. The choice of 109 CFU/ml in 0.50 ml was based on scientific evidence that bacterial viability in the range of 109 CFU/ml is adequate for colonization of the digestive tract and to produce probiotics consistently. This dose is ideally chosen in animal experiments to induce significant physiological effects such as activation of digestive enzymes, modulation of gut microbiota, and stimulation of the non-specific immune system without influencing the flora. 2.8. Outcome measure and data analysis The observed parameters included: Body weight: measured daily using a digital balance with a precision of 0.01 gm. Fecal consistency: a 3-point scale (1 = hard, 2 = soft, 3 = watery). Fecal weight: Total feces measured using a digital balance with a precision of 0.01 gm. The research data were statistically analyzed using a one-way analysis of variance (ANOVA) in the Statistical Package for the Social Sciences (SPSS). ANOVA was used to assess variation among treatment groups. If the results showed a significant difference, Duncan’s Multiple Range Test (DMRT) was used as a post hoc test to identify which groups differed significantly at the p < 0.05 level. The analysis of fecal consistency in this study was viewed using a heatmap. A heatmap of fecal consistency scores across treatment groups is shown in Table 3. Table 3.Fecal consistency scores.MiceDay 0Day 1Day 2Day 3Day 4Day 5Day 6Day 7Day 8Day 9Day 10Disease11233233222Disease11233233222Disease11233233222Disease11233233222Disease11233233222Negative11121211111Negative11121211111Negative11121211111Negative11121211111Negative11121211111Positive11233211111Positive11233211111Positive11233211111Positive11233211111Positive11233211111Treatment 111233221111Treatment 111233221111Treatment 111233221111Treatment 111233221111Treatment 111233221111Treatment 211333121111Treatment 211333121111Treatment 211333121111Treatment 211333121111Treatment 211333121111Notes: 1 = hard, 2 = soft, 3 = watery Fecal consistency scores. Notes: 1 = hard, 2 = soft, 3 = watery 3. Results and Discussion Observation of 25 mice, divided into five groups, showed significant differences (p < 0.05) in body weight, fecal consistency, and fecal weight among the treatment groups. 3.1. Body weight ANOVA analysis showed no significant differences from day 0 to 6 (p > 0.05). However, from day 7 to 10, significant differences were observed among the groups (p < 0.05). The disease control group experienced the greatest weight loss, while probiotic dose 2 exhibited the smallest reduction, with a final mean body weight of 31.04 gm. The body weight profile was provided in Table 1. Table 1.Body weight data (mean ± SD).Group (mean ± SD)ParameterNegative controlPositive controlDisease controlTreatment 1Treatment 2p-valueBody weight day 028.46 ± 1.8230.70 ± 1.5730.94 ± 2.2028.98 ± 1.8829.66 ± 2.50 0.27 Body weight day 129.36 ± 2.4332.12 ± 1.9331.70 ± 2.1829.80 ± 2.2132.58 ± 1.92 0.10 Body weight day 229.60 ± 2.2531.00 ± 1.9130.40 ± 1.5328.78 ± 1.6431.60 ± 1.90 0.17 Body weight day 330.72 ± 2.3130.22 ± 2.0729.38 ± 1.6928.06 ± 1.1930.84 ± 2.46 0.20 Body weight day 430.92 ± 2.4530.08 ± 2.1629.12 ± 1.6927.64 ± 1.3330.32 ± 2.30 0.13 Body weight day 531.24 ± 2.4030.02 ± 2.0228.66 ± 1.8728.00 ± 1.7030.68 ± 2.19 0.10 Body weight day 631.44 ± 2.4030.18 ± 2.0328.06 ± 1.6928.28 ± 1.8530.40 ± 2.27 0.09 Body weight day 731.78 ± 1.7730.04 ± 2.2127.96 ± 1.7728.50 ± 1.8130.90 ± 1.94 0.04 Body weight day 832.34 ± 1.9230.86 ± 2.3228.08 ± 1.4829.38 ± 1.4331.18 ± 2.14 0.02 Body weight day 932.48 ± 1.6931.42 ± 2.4728.92 ± 1.6029.80 ± 1.2831.58 ± 2.16 0.05 Body weight day 1032.64 ± 1.4731.84 ± 1.9628.84 ± 0.9430.60 ± 1.5631.80 ± 2.02 0.01* Note: (*) one-way ANOVA test results (p < 0.05). Body weight data (mean ± SD). Note: (*) one-way ANOVA test results (p < 0.05). 3.2. Fecal weight ANOVAs of fecal weight showed highly significant differences among groups on observation days from the start of treatment (p < 0.05). The disease control group had the highest fecal output, whereas probiotic dose 2 showed the greatest reduction, with values comparable to those of the negative control, as shown in Table 2. Table 2.Fecal weight data (mean ± SD).Group (mean ± SD)ParameterNegative controlPositive controlDisease controlTreatment 1Treatment 2p-valueFecal weight day 00.75 ± 0.00c0.69 ± 0.00e0.74 ± 0.00a0.70 ± 0.00b0.74 ± 0.00d 0.00* Fecal weight day 10.69 ± 0.00d0.91 ± 0.00a0.75 ± 0.00c0.58 ± 0.00e0.90 ± 0.00b 0.00* Fecal weight day 20.54 ± 0.00e0.94 ± 0.00a10.9 ± 0.00b1.00 ± 0.00d0.96 ± 0.00c 0.00* Fecal weight day 30.52 ± 0.00e1.00 ± 0.00a1.09 ± 0.00d0.98 ± 0.00b0.90 ± 0.00c 0.00* Fecal weight day 40.51 ± 0.00e1.22 ± 0.00a1.24 ± 0.00d0.79 ± 0.00c0.99 ± 0.00b 0.00* Fecal weight day 50.27 ± 0.00e0.82 ± 0.00a0.52 ± 0.00d0.81 ± 0.00c0.54 ± 0.00b 0.00* Fecal weight day 60.45 ± 0.00e0.59 ± 0.00a1.25 ± 0.00c0.80 ± .000d0.55 ± 0.00b 0.00* Fecal weight day 70.31 ± 0.00e0.58 ± 0.00d1.27 ± 0.00b0.50 ± 0.00a0.46 ± 0.00c 0.00* Fecal weight day 80.35 ± 0.00e0.55 ± 0.00d1.23 ± 0.00c0.28 ± 0.00a0.36 ± 0.00b 0.00* Fecal weight day 90.33 ± 0.00e0.50 ± 0.00c1.19 ± 0.00b0.27 ± 0.00a0.33 ± 0.00d 0.00* Fecal weight day 100.27 ± 0.00e0.33 ± 0.00d0.87 ± 0.00c0.27 ± 0.00a0.30 ± 0.00b 0.00* Note: (*) One-way ANOVA test results (p < 0.05) (a, b, c, d, e): data with different superscripts indicate significant differences in Duncan’s advanced test results (p < 0.05). Fecal weight data (mean ± SD). Note: (*) One-way ANOVA test results (p < 0.05) (a, b, c, d, e): data with different superscripts indicate significant differences in Duncan’s advanced test results (p < 0.05). 3.3. Fecal consistency Fecal consistency observations in Table 3. showed distinct variations among groups. In the disease control group, the feces remained mostly stable (soft to watery) all through the observation period. The negative control group, always in the hard area, scored 1, but cotrimoxazole was able to normalize the stool as soon as day 6 started. Probiotic-treated groups were experiencing earlier improvements because dose 1 was becoming stable on day 5. Dose 2 became almost normal (score 1) by day 4 and remained that way until the final time of the study. Figure 2 shows various types of fecal consistency. Fecal consistency. The results of this study show that administration of the probiotic L. lactis D4 seems to prevent diarrhea [16]. In general, there were significant differences in body weight from day 7 to day 10 when subjects received a probiotic. The progression of body weight between feeding groups may be indicative of differences in growth in the treatment groups during this procedure. This study indicates that the probiotic colonization process takes weeks to minimize the amount of S. aureus in an environment and maintain microbial equilibrium there [17, 18]. For fecal weight, significant differences between groups were detected as early as day 1 of observation, with the probiotic groups consistently showing reductions relative to the other groups. This result indicates that L. lactis D4 rapidly suppresses excessive intestinal fluid secretion. Consistent with a previous report, these results showed that L. lactis produces lactisin with potent antimicrobial activity against S. aureus [19]. The rapid response indicates that L. lactis D4 modulates intestinal physiology early by suppressing excessive intestinal fluid secretion and mitigating inflammation. This result is consistent with previous reports showing that L. lactis produces bacteriocins, such as lactisin, which have potent antimicrobial activity against S. aureus and other enteric pathogens [20, 21, 22]. Fecal consistency has been shown to follow a similar trend. The disease control group maintained scores of 2–3 (soft to watery) throughout the study, whereas the probiotic-treated groups showed earlier improvements than those treated with cotrimoxazole [23]. The probiotic group at dose 2 reached near-normal stool consistency (score 1) on day 4, which occurred more quickly than dose 1 (day 5) or cotrimoxazole (day 6), indicating that probiotics work to control the production of disease-causing bacteria and to restore health in the gut in combination with beneficial bacteria. We have also shown that probiotics are useful in regulating the immune system, in particular, in reducing inflammation and enhancing the body’s immune response, thereby improving recovery from digestive tract conditions [7, 24, 25, 26]. The promising effects of L. lactis D4, compared with cotrimoxazole, are significant. Although antibiotics effectively eradicate pathogens, they can also disrupt the commensal microbiota and delay the restoration of gut homeostasis. [27]. Probiotics have direct antimicrobial activity and restoration of microbial diversity. Lactococcus lactis strains produce short-chain fatty acids (SCFAs), particularly acetate and lactate, which reduce intestinal pH, inhibit pathogen proliferation, and serve as an energy source for colonocytes [28]. The increase in the size of the error bars at the end of the study indicates differences in the growth of the experimental animals. Some of them are natural variations among individuals and differences in their ability to utilize feed, as well as environmental influences such as housing conditions. Such differences can affect the uniformity of the animals and would also contribute to the treatment results. In general, this study suggests that L. lactis D4 has therapeutic potential as an adjunct or alternative to conventional antibiotics for the management of bacterial diarrhea. The rapid onset of action in improving fecal parameters, combined with its capacity to promote intestinal homeostasis, shows the clinical promise. Furthermore, this research contributes to the achievement of the Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being) through the development of therapeutic materials. The use of these probiotics can support improved gastrointestinal health and nutrient absorption in the context of zero hunger (SDG 2). This research also supports SDG 12 (Responsible Consumption and Production) by encouraging the use of natural ingredients in therapeutic approaches. 3.4. Strengths and limitations This study has the advantage of using L. lactis D4 from Dadiah as a local probiotic and comparing it directly with antibiotics. This provides clear evidence that probiotics have the potential to serve as an alternative treatment for diarrhea. However, this study has limitations, as it was conducted only on experimental animals and over a relatively short observation period. Therefore, its long-term effects on humans remain unknown. Further human studies are needed to confirm its benefits. 4. Conclusions In conclusion, oral administration of CMS Lactococcus lactis D4 tended to improve growth performance during the early feeding phases; however, the differences between the CMS and control groups were less pronounced in the final phase, indicating that further studies are required to confirm the long-term impact of the intervention. However, further clinical trials are required to confirm its efficacy in humans. Acknowledgment The authors thank all parties who contributed to this study. We acknowledge the staff of the Animal Product Technology Laboratory and the Faculty of Animal Husbandry. Next, the Animal House and the Pharmacology Laboratory, Faculty of Pharmacy, Universitas Andalas, provided technical assistance with animal handling, bacterial culture, and data collection. We also thank the Faculty of Pharmacy for providing experimental animals and ethical oversight. This study received no external funding. List of abbreviations ANOVA, analysis of variance; ARRIVE, Animal Research: Reporting of In Vivo Experiments; CFU, colony-forming unit; CMS, customized microbial supplementation; DMRT, Duncan’s multiple range test; LAB, lactic acid bacteria; LD4, Lactococcus lactis D4; ml, milliliter; gm, gram; CFU/ml, colony-forming unit per milliliter; MRSA, methicillin-resistant Staphylococcus aureus; SCFA, short-chain fatty acids; SPSS, statistical product and service solutions; WHO, World Health Organization. Data availability The data presented in this study are available from the corresponding author upon reasonable request. Conflicts of interest The authors declare that they have no known competing financial or non-financial interests that could have influenced the work reported in this paper. Author contributions AS and NF conceived and designed the study. AA and EB contributed to data collection, animal handling, and laboratory experiments. AA was responsible for the preparation and characterization of the probiotic strain Lactococcus lactis D4 from fermented buffalo milk (Dadiah). EE and NF performed the data analysis. All authors read and approved the final version of the manuscript. Disclaimer/Publisher’s Note The views and data expressed are solely those of the author(s) and contributor(s) and not of the publisher or editor(s). The publisher and editor(s) are not responsible for any injury or damage arising from the ideas, methods, instructions, or products mentioned. References Associated Data Data Availability Statement The data presented in this study are available from the corresponding author upon reasonable request.